HEALTH OF WOMAN. 2019.5(141): 34–37; doi 10.15574/HW.2019.141.34

Voynarovskaya G. P.
SI «Dmitry F. Chebotarev Institute of Gerontology of the National Academy of Medical Sciences of Ukraine», Kyiv

The objective: of the work is to determine the frequency of use and association with the life expectancy of individual classes and combinations of drugs for the treatment of ischemic heart disease (IHD) in patients over 60 years of age.

Materials and methods. 454 case histories of patients aged 60–90 years were analyzed. All the examined were first hospitalized in the hospital and were later observed with the main diagnosis of coronary artery disease: stable exertional angina I–IIIFC. The end points of observation were considered the last hospitalization at the time of 2017 or the onset of the end point. The patient’s death, based on which the life expectancy indicator was studied (determined by the year / age of death), was identified as the end point.

Results. It was shown that in 1997–2003, the most commonly prescribed drug classes were: β -blockers (64.8%), ACE inhibitors (іngіbіtori angіotenzinperetvoryuyuyu enzyme) 70.2%, ASA (acetylsalicylic acid) 66,2% and nitroglycerin preparations (36.4%). Statins were rarely prescribed 18.9%. In 2015–2017, drugs from the group of HMG-CoA reductase inhibitors, according to the analysis, began to be administered in 91.0% of cases. Almost not used nitroglycerin series drugs – 9.24%.

Conclusion. The results indicate that patients receiving ASA, statins and beta blockers – 81.4±3.16 years; ASA, statini and ACE inhibitors – 80.1±1.71 years; ASC, statins and blockers of Ca-channels 78.7±4.24 years. As a result of the use of logistic regression, we constructed an equation according to which the individual life expectancy of patients can be predicted depending on which drugs they treat the patient.

Key words: ischemic heart disease, patients of the elderly, features of treatment.

REFERENCES

Kovalenko VM, Kornatskyi VM. 2014. Khvoroby systemy krovoobihu yak medyko-sotsialna i suspilno-politychna problema. K: 280.

Stabilna ishemichna khvoroba sertsia (adaptovana klinichna nastanova, zasnovana na dokazakh, 2016. Arterialna gipertenziia 2 (46): 113–126. 2016.

Lutay MI. 2008. Sovremennyie printsipi medikamentoznogo lecheniya stabilnoy stenokardii. Zdorov’ya Ukrainу 3: 32–36.

Sokolov MIu, Talaieva TV ta in. 2016. Profilaktyka sertsevo-sudynnykh zakhvoriuvan. Adaptovana klinichna nastanova, zasnovana na dokazakh: 8–111.

Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group. J Hypertens 3 (4): 379–392. 1985. https://doi.org/10.1097/00004872-198508000-00011; PMid:2864374

Zharinova VIu, Voinarovska HP, Shapovalenko IS, Kuznietsova VO. 2018. Poshyrenist osnovnykh faktoriv kardiovaskuliarnoho ryzyku v osib litnoho viku z IKhS, yaki pomerly vid kardiovaskuliarnykh zakhvoriuvan, ta prohnostychna znachushchist zaznachenykh pokaznykiv. Semeinaia meditsina №6 (80):30-33

Dahlöf B, Sever PS, Poulter NR et al. 2005. Prevention of cardiovascular events with antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomized controlled trial. Lancet.  366: 895–906. https://doi.org/10.1016/S0140-6736(05)67185-1

Furberg CD, Psaty BM, Meyer JV. 1995. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 92:1326–31. https://doi.org/10.1161/01.CIR.92.5.1326; PMid:7648682

Krum H, Hill J, Fruhwald F et al. 2006. Tolerability of beta-blockers in elderly patients with chronic heart failure: the COLA-II study. Eur J Heart Fail. 8: 302–307. https://doi.org/10.1016/j.ejheart.2005.08.002; PMid:16198627

Pahor M, Guralnik JM, Corti MC, Foley DJ et al. 1995. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc. 43:1191–7. https://doi.org/10.1111/j.1532-5415.1995.tb07393.x; PMid:7594151

Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group. J Hypertens. 3(4): 379–392. 1985.   https://doi.org/10.1097/00004872-198508000-00011; PMid:2864374